Ipca Laboratories Ltd (nse:IPCALAB) Share Price

Company Profile

Business description
Ipca Laboratories Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company is an integrated pharmaceutical company manufacturing and marketing over 350 formulations and various API's covering various therapeutic segments. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), and Losartan. The company has only one reportable primary business segment, pharmaceuticals. Geographically, the maximum revenue is derived from outside India, mainly from Europe, Africa, the Americas, Asia, etc.
Contact
125, Kandivli Industrial Estate
Kandivli (West)
MumbaiMH400067
IND
T: +91 2262105000
https://www.ipca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2027
Employees
23,467

Recommended

We now forecast mildly better revenue growth and EPS growth, alongside more intense near-term cash flow pressure.

Eric Compton, CFA | 29 October 2026

We believe that investors are underappreciating the breadth and depth of Alphabet’s AI monetization and the rapid upcoming growth in Google Cloud.

Malik Ahmed Khan, CFA | 29 October 2026

Solid results included strong full-self driving software uptake and positive free cash flow.

Seth Goldstein, CFA | 29 October 2026

Index	Last price	Change	% Change
All Ordinaries	9,012.60	41.20	0.46%
CAC 40	7,970.00	83.04	1.05%
DAX 40	26,039.68	335.66	1.31%
Dow JONES (US)	52,342.56	132.54	-0.25%
FTSE 100	10,722.07	27.57	0.26%
HKSE	22,958.65	136.18	-0.59%
NASDAQ	26,184.72	365.13	-1.38%
Nikkei 225	64,659.47	705.28	1.10%
NZX 50 Index	13,698.16	12.01	-0.09%
S&P 500	7,720.39	23.59	-0.30%
S&P/ASX 200	8,891.80	44.50	0.50%
SSE Composite Index	3,651.43	30.04	-0.82%